Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial - Concepedia

Concepedia

Publication | Open Access

Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial

DOI Full Paper Access

44

Citations

12

References

2021

Year

Enrico Tiacci, Luca De Carolis, Edoardo Simonetti, Mara Merluzzi, Antonio Bennati, Vincenzo Maria Perriello, Alessandra Pucciarini, Alessia Santi, Alessandra Venanzi, Valentina Pettirossi,

Hematological MalignancyOncologyMedicinePharmacotherapyAnti-cancer AgentCancer TreatmentPharmacologyCancer ResearchBraf Inhibitor Dabrafenib

References

	Year	Citations

Page 1

Page 1